AMGN Oct 2023 245.000 call

OPR - OPR Prezzo differito. Valuta in USD.
2,9000
0,0000 (0,00%)
Al 03:59PM EDT. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente2,9000
Aperto3,0000
Denaro0,0000
Lettera0,0000
Prezzo d'esercizio245,00
Scadenza2023-10-20
Min-Max giorno2,6500 - 3,0000
Contratto - Min-MaxN/D
Volume12
Open InterestN/D
  • GlobeNewswire

    Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

    Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery